Controlled release of anti-VEGF by redox-responsive polydopamine nanoparticles

Reactive oxidative species (ROS) are the primary mediator of angiogenesis by upregulating the expression of vascular endothelial growth factor (VEGF) in the development of wet age-related macular degeneration (AMD). However, the current treatment of AMD currently relies on monthly intravitreal injec...

Full description

Saved in:
Bibliographic Details
Published in:Nanoscale 2020-08, Vol.12 (33), p.17298-17311
Main Authors: Jiang, Pengfei, Choi, Andrew, Swindle-Reilly, Katelyn E
Format: Article
Language:English
Subjects:
Age related diseases
Angiogenesis
Angiogenesis Inhibitors - therapeutic use
Antiangiogenics
Choroidal Neovascularization
Controlled release
Delayed-Action Preparations - therapeutic use
Eye diseases
Growth factors
Humans
Indoles
Macular degeneration
Nanoparticles
Oxidation-Reduction
Oxidative stress
Polymers
Scavenging
Vascular endothelial growth factor
Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factors - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Reactive oxidative species (ROS) are the primary mediator of angiogenesis by upregulating the expression of vascular endothelial growth factor (VEGF) in the development of wet age-related macular degeneration (AMD). However, the current treatment of AMD currently relies on monthly intravitreal injection of anti-angiogenic therapeutics to inhibit new choroidal angiogenesis. However, repeated injections have been associated with side-effects, are costly, and may lower patient compliance. Moreover, the intraocular oxidative stress-dependent angiogenesis is not alleviated by current treatments, which limits the overall efficacy of the treatment strategy. Recently, nanoparticle-based devices present potential in sustained delivery of angiogenesis inhibitors and excellent capability of scavenging reactive oxygen species (ROS). Nevertheless, limited efforts have been dedicated to the treatment of oxidative stress-related diseases via a combined anti-angiogenesis and anti-oxidization pathway. For this purpose, we developed anti-angiogenetic protein-loaded polydopamine (PDA) nanoparticles for the enhanced treatment of AMD. Remarkably, the PDA nanoparticles could efficiently scavenge ROS to reduce the expression of angiogenic agents. In parallel, the particles were able to controllably release loaded anti-angiogenic drugs in response to oxidative stress. A nanoparticle delivery system was developed to scavenge reactive oxygen species (ROS) and trigger release of anti-VEGF (vascular endothelial growth factor), treating two disease mechanisms associated with age-related macular degeneration (AMD).
ISSN:2040-3364
2040-3372
DOI:10.1039/d0nr03710a